University of Wisconsin
Welcome,         Profile    Billing    Logout  
 595 Trials 
2082 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Alavi, Abass
NCT00194337: Digital Mammography, Ultrasound, MRI, and PET Scans in Women With Newly Diagnosed Breast Cancer

 
2/3
400
US
breast imaging study, comparison of screening methods, magnetic resonance imaging, positron emission tomography, radiomammography, ultrasound imaging, fludeoxyglucose F 18
Abramson Cancer Center of the University of Pennsylvania, National Cancer Institute (NCI)
Breast Cancer
07/12
 
NCT00194285: FDG-PET Imaging in Painful Joint Prosthesis

Active, not recruiting
N/A
530
US
FDG-PET Imaging
University of Pennsylvania, National Institutes of Health (NIH)
Painful Joint Prostheses
02/25
02/25
NCT00194298: FDG-PET Imaging in Complicated Diabetic Foot

Active, not recruiting
N/A
240
US
FDG-PET Imaging
University of Pennsylvania, National Institutes of Health (NIH)
Diabetic Foot Disease
02/25
02/25
NCT00367666: Using Diagnostic Tools to Stage Breast Cancer

Active, not recruiting
N/A
400
US
MRI, Digital Mammography, Ultrasound and Positron Emission Tomography (PET)
University of Pennsylvania
Breast Cancer
03/25
03/25
Hochster, Howard S
SOLARIS, NCT04094688: Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients with Advanced or Metastatic Colorectal Cancer

Active, not recruiting
3
455
US
Bevacizumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride, Irinotecan, Cholecalciferol, Vitamin D3, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Colorectal Adenocarcinoma
01/26
07/26
COMMIT, NCT02997228: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the Study

Recruiting
3
120
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, Elplat, JM 83, JM-83, JM83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, RP54780, SR 96669, SR-96669, SR96669, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI), NRG Oncology
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
06/27
06/27
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers

Active, not recruiting
2/3
150
US
CTX-009, Paclitaxel
Compass Therapeutics
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
07/25
12/25
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
NCT05296681: Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery

Recruiting
2
42
US
NBT-NM108
Howard S. Hochster, MD
Metastatic Colon Carcinoma, Stage IV Colon Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8
07/25
07/25
NCT04294264: TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

Active, not recruiting
2
50
US
Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Trifluridine and Tipiracil Hydrochloride, Lonsurf, TAS 102, TAS-102, Tipiracil Hydrochloride Mixture with Trifluridine, Trifluridine/Tipiracil, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
Rutgers, The State University of New Jersey, National Cancer Institute (NCI)
Metastatic Colorectal Carcinoma, Recurrent Colon Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colon Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7
03/24
03/26
QUIC, NCT06048133: Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers

Recruiting
2
39
US
Gemcitabine, Cisplatin, Zimberelimab, AB122, Quemliclustat, AB680
Nataliya Uboha, Arcus Biosciences, Inc., Gilead Sciences, University of Wisconsin, Madison
Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
01/25
07/25
NCT05167409: A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

Active, not recruiting
2
48
US
Evorpacept (ALX148), evorpacept, Cetuximab, Erbitux, Pembrolizumab, Keytruda
University of Colorado, Denver, ALX Oncology Inc., Merck Sharp & Dohme LLC, Eli Lilly and Company, Criterium, Inc., Academic GI Cancer Consortium (AGICC)
Microsatellite Stable Metastatic Colorectal Cancer
12/25
03/26
The AB7 Trial, NCT04829383: A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

Active, not recruiting
2
50
US
Atezolizumab, Tecentriq, Bevacizumab, Avastin
Howard S Hochster, Genentech, Inc., Rutgers Cancer Institute of New Jersey
Unresectable Hepatocellular Carcinoma
10/24
10/25
NCT04169347: FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Active, not recruiting
2
27
US
Oxaliplatin, Irinotecan, Leucovorin, Panitumumab
Criterium, Inc., Amgen
Colorectal Cancer Metastatic
12/24
01/25
SCOTI, NCT05806931: Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer

Recruiting
2
50
US
TAS-102, oxaliplatin, irinotecan with bevacizumab
Rutgers, The State University of New Jersey
Colon Cancer, Rectal Cancer
05/26
05/27
NCT05296421: Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer

Recruiting
N/A
16
US
Biopsy, BIOPSY_TYPE, Bx, Therapeutic Conventional Surgery, Uniformly-labeled [13C]glucose, [U-13C] Glucose, U-13C-Glucose
Rutgers, The State University of New Jersey, National Cancer Institute (NCI)
Pancreatic Ductal Adenocarcinoma
03/25
07/26
Bailey, Howard H
ACCIO, NCT04267848: Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial

Recruiting
3
1210
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Observation, Inspection, Visual Inspection, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Questionnaire Administration
National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
12/25
12/25
NCT05455658: STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Recruiting
2
33
US
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, CD105/Yb-1/SOX2/CDH3/MDM2 Plasmid Vaccine, STEMVAC, STEMVAC Th1 Polyepitope Plasmid-based Vaccine, Sargramostim, 123774-72-1, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
University of Washington, National Cancer Institute (NCI), University of Wisconsin, Madison
Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
04/25
12/25
NCT05107219: GCC Agonist Signal in the Small Intestine

Recruiting
1
43
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Esophagogastroduodenoscopy, EGD, Linaclotide, [9-L-tyrosine]heat-stable enterotoxin (Escherichia coli)-(6-19)-peptide, Linzess, MD-1100, Plecanatide, Trulance
National Cancer Institute (NCI)
Barrett Esophagus, Gastroesophageal Reflux Disease, Malignant Digestive System Neoplasm
02/25
02/25
Hutson, Paul R
NCT05467761: Bioavailability Study of Psilocybin in Normal Adults

Withdrawn
1
8
US
Oral Psilocybin, IV Psilocybin
University of Wisconsin, Madison, TRYP Therapeutics
Healthy
03/24
03/24
NCT06378528: Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP)

Not yet recruiting
1
5
US
Ketamine, Ketamine Assisted Psychotherapy, SmartSleep EEG recording headband
University of Wisconsin, Madison
Posttraumatic Stress Disorder
03/26
03/26
Ward, Michael M
STARA, NCT01793519: Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis

Active, not recruiting
4
290
US
Etanercept, Enbrel, Infliximab, Remicade, Adalimumab, Humira, Placebo
Georgetown University, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), University of Maryland, Baltimore, Washington D.C. Veterans Affairs Medical Center, Medstar Health Research Institute, Patient-Centered Outcomes Research Institute, Arthritis and Pain Associates of PG County, Arthritis & Rheumatism Associates, P.C., Rheumatology Associates of Baltimore, L.L.C., The Arthritis Clinic of Northern Virginia, P.C., Arthritis and Rheumatic Disease Associates, P.C.
Rheumatoid Arthritis
06/24
08/24
Shah, Manish A
SU2C ACT3, NCT03803553: Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Recruiting
3
400
US
FOLFIRI Protocol, FOLinic acid-Fluorouracil-IRInotecan regimen, ACTIVE SURVEILLANCE, Nivolumab Protocol, Nivolumab, Encorafenib/Binimetinib/Cetuximab Protocol, Enco/Bini/Cetux, Trastuzumab + Pertuzumab, Herceptin
Massachusetts General Hospital, Stand Up To Cancer
Metastatic Colon Cancer, Stage III Colon Cancer
12/26
12/27
PediDOSE, NCT05121324: Pediatric Dose Optimization for Seizures in Emergency Medical Services

Recruiting
3
6000
US
Standardized seizure protocol, midazolam, Conventional seizure protocol
Stanford University, National Institute of Neurological Disorders and Stroke (NINDS), University of Utah, Baylor College of Medicine
Seizures
07/26
09/26
A022102, NCT05677490: MFOLFIRINOX Versus MFOLFOX with or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Recruiting
3
382
US
Fluorouracil, 2,4-Dioxo-5-fluoropyrimidine, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluoro-2,4(1H,3H)-pyrimidinedione,, Leucovorin Calcium, 1492-18-8, 5-Formyl Tetrahydrofolate, Calcium (6S)-Folinate, Calcium Folinate, Oxaliplatin, 1-OHP, Dacotin, Dacplat, ELOXATIN, Irinotecan, Nivolumab, MDX-1106, Opdivo, Magnetic Resonance Imaging, MRI, Computed Tomography, CAT Scan, Computed Axial Tomography, CT Scan, Biospecimen Collection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC V8, Clinical Stage III Gastric Cancer AJCC V8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC V8, Clinical Stage IV Esophageal Adenocarcinoma AJCC V8, Clinical Stage IV Gastric Cancer AJCC V8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC V8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
11/28
11/28
NCT03146962: High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies

Completed
2
61
US
Vitamin C, Ascorbic Acid
Weill Medical College of Cornell University, Stand Up To Cancer
Colorectal Cancer, Pancreatic Cancer, Lung Cancer
04/23
04/23
NCT03921021: Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Completed
2
17
US
Telomelysin, OBP-301
Weill Medical College of Cornell University, Oncolys BioPharma Inc
Esophagogastric Adenocarcinoma
06/23
07/23
NCT02998268: Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma

Active, not recruiting
2
42
US
Pembrolizumab, Keytruda, Taxol, Paclitaxel, Carboplatin
Weill Medical College of Cornell University, Merck Sharp & Dohme LLC
Esophageal Adenocarcinoma
02/21
09/26
CA209-76L, NCT04021108: Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol )

Active, not recruiting
2
80
US
Nivolumab 240 MG
Weill Medical College of Cornell University, Bristol-Myers Squibb
Gastroesophageal Adenocarcinoma
04/25
04/26
NCT06300463: Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

Recruiting
2
24
US
Botensilimab, AGEN1181, Balstilimab, AGEN2034, AGEN1423, Radiation
Weill Medical College of Cornell University, Agenus Inc.
Colorectal Cancer Metastatic, Liver Metastases, Colorectal Cancer
09/25
03/27
NCT06340711: Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Recruiting
2
27
US
OBP-301, Suratadenoturev, Pembrolizumab, Keytruda
Weill Medical College of Cornell University, Merck Sharp & Dohme LLC, Oncolys BioPharma Inc
Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
04/26
04/28
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
NCT05480384: Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Recruiting
2
25
US
Nivolumab, OPDIVO, Trastuzumab deruxtecan, ENHERTU
Brown University, AstraZeneca
Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression, Gastroesophageal-junction Cancer
01/25
01/27
KEYNOTE-E58, NCT04041310: Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Active, not recruiting
1/2
115
Europe, Canada, US
GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®, pembrolizumab
Nouscom SRL, Merck Sharp & Dohme LLC
Solid Tumor, Adult
04/25
11/26
KISIMA-01, NCT04046445: Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

Active, not recruiting
1
96
Europe, US
ATP128, BI 754091, Ezabenlimab, VSV-GP128
Amal Therapeutics, Boehringer Ingelheim
Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer, Metastatic Colorectal Cancer, Liver Metastasis Colon Cancer
05/25
08/25
NCT04144699: Clinical Validation of Omron WheezeScan

Recruiting
N/A
240
US
Omron Healthcare Co., Ltd., University of Wisconsin, Madison, Children's Hospital Medical Center, Cincinnati, University of Chicago
Asthma in Children, Bronchitis, Bronchiolitis
11/21
12/21
PIVoTAL-IDE, NCT04505163: Left Atrial Posterior Wall and PV Isolation Using Cryoballoon for Treatment of Persistent AF

Active, not recruiting
N/A
153
US
Standard Cryoballoon Pulmonary Vein Isolation (PVI), Arctic Front Advance Cardiac Cryoablation System, Cryoballoon PVI + Posterior Wall Isolation
Dignity Health Medical Foundation, Mercy General Hospital and Dignity Health Medical Foundation, Beth Israel Deaconess Medical Center, UC Health Medical Center, MedStar Georgetown University Hospital and Medical Center, Tampa Cardiac Specialists, Bethesda North Hospital, Brigham and Women's Hospital, Texas Cardiac Arrhythmia Institute At St. Davids Medical Center, St. Luke's Hospital and Health Network, Pennsylvania, Sarasota Memorial Health Care System, Nebraska Methodist Hospital-Methodist Physicians Clinic
Persistent Atrial Fibrillation
04/24
12/24
NCT05809596: HEAL-LAA Clinical Trial

Active, not recruiting
N/A
949
US
WATCHMAN FLX Pro LAAC Device, Left Atrial Appendage Closure
Boston Scientific Corporation
Atrial Fibrillation, Bleeding, Stroke
07/24
08/25
CATALYST, NCT04226547: Amplatzer Amulet LAAO Vs. NOAC

Recruiting
N/A
2650
Europe, Canada, Japan, US, RoW
Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Amplatzer Amulet LAA Occluder, Non-Vitamin K Oral Antagonists, NOAC
Abbott Medical Devices
Atrial Fibrillation, Stroke, Bleeding
08/27
08/30
NCT02164409: Changes Associated With H. Pylori and Gastric Carcinogenesis

Recruiting
N/A
120
US
Endoscopy tissue collection
Weill Medical College of Cornell University
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
04/25
04/25
NCT02535936: Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

Recruiting
N/A
15
US
3Tesla MRI with DTI-MRI and rsfcMRI under general anesthesia
The University of Texas Health Science Center, Houston
Spastic Diplegia
01/30
01/31
DTI/SEP, NCT02846272: Diffusion Tensor and Functional Connectivity Imaging in Pediatric Epilepsy: Imaging/Histology Correlation

Recruiting
N/A
50
US
Observation
The University of Texas Health Science Center, Houston
Intractable Epilepsy
01/30
01/31
Asthana, Sanjay
KEEPS, NCT00623311: Cognitive and Affective Study

Active, not recruiting
4
720
US
oral conjugated equine estrogens, transdermal estradiol, micronized progesterone, Placebo
University of Wisconsin, Madison, Kronos Longevity Research Institute, University of Utah, University of California, Albert Einstein College of Medicine of Yeshiva University, Brigham and Women's Hospital, Columbia University, Mayo Clinic, University of Washington, Yale University
Perimenopause, Coronary Disease, Estrogen Replacement Therapy, Hormone Replacement Therapy
04/12
04/12
Green, Rebecca P
NCT04099290: Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
N/A
50
US
Blood and tumor samples
UNC Lineberger Comprehensive Cancer Center, American Society of Clinical Oncology, National Cancer Institute (NCI)
Head and Neck Neoplasm, Carcinoma, Squamous Cell
02/26
02/26
Jarrard, David
NCT06022822: Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

Recruiting
2
90
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Placebo Administration, Urolithin A Supplement, Mitopure, Uro-A Supplement
National Cancer Institute (NCI)
Prostate Adenocarcinoma
11/26
05/27
NCT03232164: PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer

Completed
1
126
US
18F-DCFPyL PET
University of Wisconsin, Madison
Prostate Cancer, Prostate Neoplasm
11/24
11/24
McNeel, Douglas
NCI-2019-07273, NCT04090528: pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Active, not recruiting
2
60
US
pTVG-HP, pTVG-AR, Pembrolizumab, Keytruda
University of Wisconsin, Madison, Merck Sharp & Dohme LLC, Madison Vaccines Incorporated, Prostate Cancer Foundation
Castration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer
11/24
10/26
SYNERGY-201, NCT06228053: Study of SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer

Recruiting
2
53
US
SX-682, Enzalutamide, Xtandi
Syntrix Biosystems, Inc., National Cancer Institute (NCI)
Metastatic Castration-resistant Prostate Cancer
06/26
06/28
NCT02499835: Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

Completed
1/2
66
US
Pembrolizumab, 1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1), Lambrolizumab, Keytruda, MK-3475, SCH 900475, pTVG-HP Plasmid DNA Vaccine
University of Wisconsin, Madison, Prostate Cancer Foundation, Madison Vaccines, Inc
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
08/21
07/23
PRESERVE-006, NCT05682443: ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Recruiting
1/2
144
US
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody, Gotistobart, lutetium Lu 177 vipivotide tetraxetan, IV infusion, Q6W for up to 6 doses., Pluvicto
OncoC4, Inc., Prostate Cancer Clinical Trials Consortium
Metastatic Castration-resistant Prostate Cancer
06/26
06/27
PHAROS, NCT06705686: Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer

Not yet recruiting
1
30
US
(R)-9bMS, Mahatinib
TechnoGenesys, Inc., National Cancer Institute (NCI), Washington University School of Medicine, University of Wisconsin, Madison
Metastatic Castration-resistant Prostate Cancer (CRPC), Metastatic Castration-resistant Prostate Carcinoma
03/26
03/28
Paulsen, Jane S
PREDICT-HD, NCT00051324: Neurobiological Predictors of Huntington's Disease

Active, not recruiting
N/A
1700
US
Jordan Schultz, National Institute of Neurological Disorders and Stroke (NINDS)
Huntington Disease
06/25
06/25
CADASIL, NCT05677880: Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy () Study

Recruiting
N/A
500
US
Study Procedures
University of Wisconsin, Madison, National Institute on Aging (NIA)
CADASIL
01/26
01/26
PREVENT-HD, NCT04818060: Preparing for Prevention of Huntington's Disease

Recruiting
N/A
258
US
Clinical Assessments, MRI Scan, Lumber Puncture (LP)
University of Wisconsin, Madison, National Institute of Neurological Disorders and Stroke (NINDS)
Huntington Disease
02/25
02/25
NCT05567744: Registry for CADASIL

Recruiting
N/A
2500
US
Registry
University of Wisconsin, Madison
Cerebral Autosomal Dominant Ateriopathy With Subcortical Infarcts and Leukoencephalopathy
10/27
10/27
Juckett, Mark B
NCT03870750: Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases

Active, not recruiting
2/3
455
US
Supportive Palliative Care, Comfort Care, palliation, palliative care, palliative therapy, Palliative Treatment, Symptom Management, Symptoms Management, PA-Palliative Therapy, Clinical Management, Best Practice, standard of care, standard therapy, Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Questionnaire Administration, Quality-of-Life Assessment, Quality of Life Assessment, Survey Administration
Fred Hutchinson Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH)
Hematopoietic and Lymphoid Cell Neoplasm, Non-Neoplastic Hematologic and Lymphocytic Disorder
12/25
12/25
OPTIMIZE, NCT06001385: HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

Recruiting
2
190
US
Busulfan, Busulfex®, Fludarabine, Fludara®, PBSC Hematopoietic Stem Cell Transplantation (HSCT), PBSC HSCT, PBSC HCT, PBSC Transplantation, PBSCT, Post-Transplant Cyclophosphamide, Cytoxan®, PTCy, Mesna, Mesnex®, Tacrolimus, Mycophenolate Mofetil, MMF, Cellcept®, Patient Reported Outcomes, PRO, Melphalan, Total-body irradiation, TBI, Cyclophosphamide
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
02/26
06/26
NCT05805605: Allo HSCT Using RIC and PTCy for Hematological Diseases

Recruiting
2
56
US
Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant, Total Body Irradiation, Sirolimus Pill, Mycophenolate Mofetil, (MMF)
Masonic Cancer Center, University of Minnesota
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Myelodysplastic Syndrome With Excess Blasts-1, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Myeloproliferative Neoplasm, Myelofibrosis
10/27
10/28
ZN-d5-004C, NCT05682170: Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

Hourglass Jul 2024 - Dec 2024 : Preliminary data r/r/ AML
Terminated
1/2
40
US
ZN-d5 ZN-c3, Study Drug, ZN-c3
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Acute Myeloid Leukemia (AML)
07/24
07/24
TRX103-01, NCT06462365: Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

Recruiting
1
36
US
TRX103
Tr1X, Inc.
Hematologic Malignancy, GvHD, GVHD,Acute, GVHD, Chronic, Hematopoietic Stem Cell Transplant, Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, Adult T-Cell, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, in Remission, Cancer Remission
04/26
04/27
NCT06594445: HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

Recruiting
1
45
US
GTB-360, anti-CD16/IL-15/anti-CD33
Masonic Cancer Center, University of Minnesota
Myeloid Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes
03/27
10/27
KOMET-007, NCT05735184: A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients with AML

Recruiting
1
212
US
Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine
Kura Oncology, Inc.
Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML with Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma
05/26
05/27
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
Mulkerin, Daniel
NCT05102721: Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma

Recruiting
1b/2
48
US
Avelumab and Pepinemab
Vaccinex Inc., University of Rochester
Metastatic Pancreatic Adenocarcinoma
12/28
12/28
NCT04477343: A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
1
20
US
SX-682, Nivolumab Injectable Product
University of Rochester, Syntrix Biosystems, Inc., Bristol-Myers Squibb
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
01/25
12/25
Barrett, Bruce
NOSES, NCT06076304: Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Sinusitis

Active, not recruiting
4
3720
US
Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet, Augmentin, Placebo, Inactive, Control, Budesonide nasal spray, Rhinocort, C-reactive protein, CRP
Daniel Merenstein, Patient-Centered Outcomes Research Institute, Medstar Health Research Institute, Penn State College of Medicine, University of Washington, Virginia Commonwealth University, University of California, Los Angeles, University of Wisconsin, Madison
Sinus Infection, Acute Sinusitis
10/28
12/28
Kahl, Brad S
RESORT, NCT00075946: Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

Checkmark P3 data - ASCO
Jun 2012 - Jun 2012: P3 data - ASCO
Checkmark P3 subgroup data -ASCO
Jun 2012 - Jun 2012: P3 subgroup data -ASCO
Completed
3
545
US
rituximab
Eastern Cooperative Oncology Group, National Cancer Institute (NCI)
Lymphoma
09/13
08/21
S2308, NCT06337318: Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Recruiting
3
600
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human
National Cancer Institute (NCI)
Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
03/32
03/32
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
EVOLVE CLL/SLL, NCT04269902: Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), Study

Recruiting
3
247
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA 101, GA-101, GA101, Gazyva, huMAB(CD20), R 7159, R-7159, R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
10/28
10/28
NCT05976763: Testing Continuous Versus Intermittent Treatment with the Study Drug Zanubrutinib for Older Patients with Previously Untreated Mantle Cell Lymphoma

Recruiting
3
421
US
Zanubrutinib, Rituximab, Patient Observation, Bone Marrow Biopsy, Fludeoxyglucose F-18, Positron Emission Tomography, PET, Computed Tomography, CAT Scan, CT Scan, Magnetic Resonance Imaging, MRI, Esophagogastroduodenoscopy, EGD, Colonoscopy, Biospecimen Collection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Mantle Cell Lymphoma
08/38
08/38
NCT03623373: Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

Active, not recruiting
2
13
US
Bendamustine, Treanda, Bendeka, Rituximab, Rituxan, Rituxan Hycela, Acalabrutinib, Calquence®, Cytarabine, Cytosar-U, Leukapheresis, Peripheral blood, Oral rinse, Bone marrow collection
Washington University School of Medicine, Acerta Pharma BV
Mantle Cell Lymphoma
02/20
02/25
SWOG S1608, NCT03269669: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Active, not recruiting
2
95
US
Bendamustine Hydrochloride, Belrapzo, Bendamustin Hydrochloride, Bendeka, CEP 18083, CEP-18083, CEP18083, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treakisym, Treanda, VIVIMUSTA, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Echocardiography, EC, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA 101, GA-101, GA101, Gazyva, huMAB(CD20), R 7159, R-7159, R7159, RO 5072759, RO-5072759, RO5072759, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Umbralisib, 2-((1S)-1-(4-Amino-3-(3-fluoro-4-(1-methylethoxy)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one, RP-5264, RP5264, TGR 1202, TGR-1202, TGR1202, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
12/25
12/25
EA4181, NCT04115631: A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Active, not recruiting
2
360
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Bendamustine, SDX-105, Bendamustine Hydrochloride, Bendamustin Hydrochloride, Bendeka, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Liver Lymphoma, Mantle Cell Lymphoma
12/25
12/25
CNS-PHLAT, NCT06687772: CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma with Thiotepa-based Autologous Stem Cell Transplant

Not yet recruiting
2
36
US
Thiotepa, Carmustine, Autologous Stem Cell Transplant, ASCT, Anthracycline-based induction chemotherapy
Washington University School of Medicine
Diffuse Large B Cell Lymphoma
08/27
08/29
NCT05410418: Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

Recruiting
2
34
US
Mosunetuzumab, RO7030816, BTCT4465A, Polatuzumab vedotin, RO5541077, DCDS4501A
Washington University School of Medicine, Genentech, Inc., Institute for Follicular Lymphoma
Lymphoma, Follicular, Follicular Lymphoma
10/26
10/31
NCT04659044: Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Terminated
2
3
US
Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma
03/24
03/24
NCT02756962: Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

Active, not recruiting
2
107
US
Cytarabine, Ara-C, Cytosar-U, Tarabine-PFS, AraC, Allogeneic stem cell transplant, AlloSCT, Bone marrow aspiration, Punch skin biopsy, ClinSeq
Washington University School of Medicine, The Leukemia and Lymphoma Society, American Society of Hematology
Acute Myeloid Leukemia
07/29
07/29
NCT06040320: Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

Recruiting
1/2
12
US
Polatuzumab vedotin, Polivy, Rituximab, Rituxan, CHP
Washington University School of Medicine
Post-transplant Lymphoproliferative Disorder
05/26
05/31
NCT02728531: Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

Completed
1
18
US
Bendamustine, Bendamustine Hydrochloride, Treanda, Rituximab, Rituxan, Cytarabine, Cytosar-U, Tarabine PFS, Pegfilgrastim, Neulasta, G-CSF, Leukapheresis, Filgrastim, Neupogen, Autologous stem cell transplant
Washington University School of Medicine
Mantle Cell Lymphoma
01/19
08/23
NCT05412290: Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

Recruiting
1
15
US
Mosunetuzumab, RO7030816, BTCT4465A
Washington University School of Medicine, Genentech, Inc.
B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Follicular Lymphoma Grade 3
07/27
06/29
NCT06008808: Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Recruiting
1
49
US
Ruxolitinib, Jakafi
Washington University School of Medicine, Incyte Corporation
Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease
09/26
12/26
NCT05464329: Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma

Recruiting
1
24
US
Mosunetuzumab, RO7030816, BTCT4465A, DHAX, ICE
Washington University School of Medicine, Genentech, Inc.
Large B-cell Lymphoma, High-grade B-cell Lymphoma, Transformed B-Cell Lymphoma, Follicular Lymphoma Grade 3B
05/26
05/30
Traynor, Anne
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
03/25
03/28
EA5163, NCT03793179: Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Active, not recruiting
3
600
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
09/27
09/27
EA5181, NCT04092283: Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Active, not recruiting
3
660
US, RoW
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt
National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
12/28
12/28
ALCHEMIST, NCT02201992: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An Treatment Trial)

Recruiting
3
168
US, RoW
Clinical Observation, Crizotinib, MET tyrosine kinase inhibitor PF-02341066, PF-02341066, PF-2341066, Xalkori, Laboratory Biomarker Analysis
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
05/36
05/36
Lung-MAP Non-Match Sub-Study, NCT05096663: Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Checkmark Initiation of Lung-MAP trial in combination with Keytruda for 2L NSCLC
Apr 2022 - Apr 2022: Initiation of Lung-MAP trial in combination with Keytruda for 2L NSCLC
Active, not recruiting
2/3
82
US
Cobalamin, B12 Vitamin, Cobalamin (1+), VIT B12, Vitamin B-12, Vitamin B12, Vitamin-B12, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Folic Acid, 2-[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]aminopentanedioic acid, FA, Folacin, Pteroylmonoglutamic Acid, Vitamin B9, Vitamin Bc, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Nogapendekin Alfa, ALT 803, ALT-803, ALT803, Fusion Protein Consisting of IL-15N72D and IL-15RaSu/FC, IL-15N72D/IL-15Ra-Fc, IL-15N72D:IL-15RaSu/Fc Fusion Complex, N 803, N-803, N803, Superagonist Interleukin-15:Interleukin-15 Receptor AlphaSu/Fc Fusion Complex Alt-803, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2
SWOG Cancer Research Network, National Cancer Institute (NCI)
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
02/27
12/27
BTCRC-LUN19-396, NCT04367311: Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

Recruiting
2
100
US
Atezolizumab, Docetaxel, Cisplatin, Pemetrexed
Nasser Hanna, Genentech, Inc.
Lung Cancer, NSCLC
09/25
01/26
BTCRC LUN20-462, NCT04919382: Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

Recruiting
2
56
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
Dwight Owen, Genentech, Inc.
Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
12/25
12/26
BTCRC-LUN18-153, NCT04317534: Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Recruiting
2
244
US
Pembrolizumab
Greg Durm, MD, Merck Sharp & Dohme LLC
NSCLC, Stage I
04/26
04/29
MATISSE, NCT05742607 / 2022-001903-42: IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer

Recruiting
2
70
Europe, US
IPH5201 + durvalumab + standard chemotherapy, Durvalumab, MEDI4736, IMFINZI, Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy, Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy, Pemetrexed/Carboplatin Pemetrexed/Carboplatin as chemotherapy
Innate Pharma, Innate Pharma SA
Non Small Cell Lung Cancer
06/25
09/26
NCT04227028: Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

Active, not recruiting
1
5
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Brigatinib, Alunbrig, AP 26113, AP-26113, AP26113
City of Hope Medical Center, National Cancer Institute (NCI)
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
06/25
06/25
NCT04146571: Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Available
N/A
US
Ensartinib, X-396, X396
Xcovery Holding Company, LLC
Non-Small Cell Lung Cancer, ALK Gene Rearrangement Positive
 
 
ALCHEMIST Screening, NCT02194738: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The Trial)

Recruiting
N/A
8300
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Clinical Observation, observation, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Crizotinib, Alkixen, Crizocent, MET Tyrosine Kinase Inhibitor PF-02341066, PF 02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cytology Specimen Collection Procedure, Cytologic Sampling, Echocardiography, EC, Erlotinib, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Placebo Administration, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
09/26
09/26
Portnow, Jana
NCT05139043: Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors

Active, not recruiting
2
26
US
Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex
City of Hope Medical Center, National Cancer Institute (NCI)
Malignant Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain, Recurrent Malignant Brain Neoplasm
09/25
09/25
NCT05388435: Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

Terminated
1/2
17
US
SKL27969
SK Life Science, Inc.
Advanced Solid Tumor
03/24
03/24
NCT05432804: Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Recruiting
1/2
97
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT 330, KPT-330, KPT330, Nexpovio, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
National Cancer Institute (NCI)
MGMT-Methylated Glioblastoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
06/26
06/26
NCT02338037: Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors

Completed
1
8
US
Therapeutic Conventional Surgery, Biopsy, Bx, Eribulin Mesylate, E7389, ER-086526, Microdialysis, Pharmacological Study, pharmacological studies
City of Hope Medical Center, National Cancer Institute (NCI), Eisai Inc.
Metastatic Malignant Neoplasm in the Adult Brain, Primary Brain Tumor
08/17
03/24
NCT05139056: Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas

Recruiting
1
36
US
Neural Stem Cells-expressing CRAd-S-pk7, CRAd-S-pk7 loaded NSCs, NSC-CRAd-S-pk7, NSC-CRAd-S-pk7 Virotherapeutic, NSCs loaded with CRAd-S-pk7, SC-CRAd-Survivin-pk7, Resection, Surgical Resection
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma, Recurrent Anaplastic Oligodendroglioma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
08/25
08/25
 

Download Options